StockNow
Calendar
Log in
U.S. Markets

New Phase 3b data show Eli Lilly's (LLY) EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand dermatitis; primary endpoint met

StockNow breaking-news AI analysis

The headline reports improved skin clearance, itch, pain, and patient satisfaction with EBGLYSS in moderate-to-severe hand and foot atopic dermatitis; detailed trial results are unavailable.

1 stocks
LLYEli Lilly & Co.$1,186.30Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Israeli press reports growing assessments that the incident aboard the Flydubai plane was a terrorist attack, Al Jazeera adds; reports suggest the co-pilot who stabbed the other pilot was of Omani origin

Geopolitics

Senior source says mediators are working to return negotiations to a broader track that includes the nuclear issue, Al Hadath reports

Commodities

OPEC+ oil producers are reportedly set to keep output targets unchanged at this Sunday's meeting, sources suggest